Next Article in Journal
Expression of A New Endogenous Retrovirus-Associated Transcript in Hodgkin Lymphoma Cells
Next Article in Special Issue
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
Previous Article in Journal
Autophagy Modulation in Human Thyroid Cancer Cells following Aloperine Treatment
Previous Article in Special Issue
Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer—From Basic Research to Potential Clinical Applications
Review

The Landscape of Actionable Gene Fusions in Colorectal Cancer

1
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy
2
Unit of Molecular Cytogenetics, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milano, Italy
3
Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(21), 5319; https://doi.org/10.3390/ijms20215319
Received: 17 September 2019 / Revised: 23 October 2019 / Accepted: 23 October 2019 / Published: 25 October 2019
(This article belongs to the Special Issue Molecular and Translational Research on Colorectal Cancer)
The treatment scenario of metastatic colorectal cancer (mCRC) has been rapidly enriched with new chemotherapy combinations and biological agents that lead to a remarkable improvement in patients’ outcome. Kinase gene fusions account for less than 1% of mCRC overall but are enriched in patients with high microsatellite instability, RAS/BRAF wild-type colorectal cancer. mCRC patients harboring such alterations show a poor prognosis with standard treatments that could be reversed by adopting novel therapeutic strategies. Moving forward to a positive selection of mCRC patients suitable for targeted therapy in the era of personalized medicine, actionable gene fusions, although rare, represent a peculiar opportunity to disrupt a tumor alteration to achieve therapeutic goal. Here we summarize the current knowledge on potentially actionable gene fusions in colorectal cancer available from retrospective experiences and promising preliminary results of new basket trials. View Full-Text
Keywords: gene fusions; colorectal cancer; translocation; biomarker gene fusions; colorectal cancer; translocation; biomarker
Show Figures

Figure 1

MDPI and ACS Style

Pagani, F.; Randon, G.; Guarini, V.; Raimondi, A.; Prisciandaro, M.; Lobefaro, R.; Di Bartolomeo, M.; Sozzi, G.; de Braud, F.; Gasparini, P.; Pietrantonio, F. The Landscape of Actionable Gene Fusions in Colorectal Cancer. Int. J. Mol. Sci. 2019, 20, 5319. https://doi.org/10.3390/ijms20215319

AMA Style

Pagani F, Randon G, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, Pietrantonio F. The Landscape of Actionable Gene Fusions in Colorectal Cancer. International Journal of Molecular Sciences. 2019; 20(21):5319. https://doi.org/10.3390/ijms20215319

Chicago/Turabian Style

Pagani, Filippo, Giovanni Randon, Vincenzo Guarini, Alessandra Raimondi, Michele Prisciandaro, Riccardo Lobefaro, Maria Di Bartolomeo, Gabriella Sozzi, Filippo de Braud, Patrizia Gasparini, and Filippo Pietrantonio. 2019. "The Landscape of Actionable Gene Fusions in Colorectal Cancer" International Journal of Molecular Sciences 20, no. 21: 5319. https://doi.org/10.3390/ijms20215319

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop